Sign inCreate account

Report workspace tools

NCT01848470COMPLETEDanonymous

Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of Multiple Ascending Doses of CG400549 in Healthy Volunteers

Sponsor

Source record

CrystalGenomics, Inc.

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

CG400549

Indication / condition

AI-normalized

Healthy

Intervention

Source record

CG400549 640mg, CG400549 320 mg, CG400549 640 mg, CG400549 960 mg, Placebo 640mg, Placebo 320mg, placebo 960 mg, Placebo 640mg

Source & freshness

Source record

NCT ID

NCT01848470

Original source

ClinicalTrials.gov

Source last updated

May 07, 2013

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01848470

Title

Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of Multiple Ascending Doses of CG400549 in Healthy Volunteers

Sponsor

CrystalGenomics, Inc.

Status

COMPLETED

Phase

PHASE1

Condition raw

Healthy

Condition normalized

Healthy

Modality raw

Healthy

Modality normalized

small molecule

Target raw

CG400549

Target normalized

CG400549

Interventions

CG400549 640mg, CG400549 320 mg, CG400549 640 mg, CG400549 960 mg, Placebo 640mg, Placebo 320mg, placebo 960 mg, Placebo 640mg

Public preview

Source record

CrystalGenomics, Inc. conducted a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CG400549 in healthy male volunteers. The study involved multiple ascending doses and was randomized, double-blind, and placebo-controlled.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of Multiple Ascending Doses of CG400549 in Healthy Volunteers

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01848470

Status

COMPLETED

Phase

PHASE1

Sponsor

CrystalGenomics, Inc.

Executive brief

Investment-Ready Snapshot

CrystalGenomics, Inc. conducted a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CG400549 in healthy male volunteers. The study involved multiple ascending doses and was randomized, double-blind, and placebo-controlled.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 07, 2013
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01848470

Indication

Healthy

Modality

small molecule

Target

CG400549

Intervention

CG400549 640mg, CG400549 320 mg, CG400549 640 mg, CG400549 960 mg, Placebo 640mg, Placebo 320mg, placebo 960 mg, Placebo 640mg

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.